Austin doctor studying a new kind of medication for major depressive disorder
While drug companies have created many medications that help increase serotonin, that neurotransmitter chemical that is our natural mood stabilizer in the brain, only about 60% to 70% of patients will respond to those medications, Garcia said.
The major depressive disorder medication, BHV-7000, is different than those that focus on serotonin because it focuses on potassium channels, which help regulate the activity of neurons in the brain.
The channels "could help calm the brain and get it back to a normal state," Garcia said. "This is an interesting hypothesis."
Garcia and his company Austin Clinical Trial Partners are enrolling up to 306 people ages 18 to 75 in a trial to study the drug, which is made by the biopharmaceutical company Biohaven.
For the trial, Garcia is looking for people who are having a major depressive disorder episode lasting two months up to 24 months. They must stop taking their depression medication at least two weeks prior to enrolling in the study, and cannot be having suicidal thoughts.
Interested participants will receive a physical exam and testing to make sure they are medically stable before beginning the study.
Garcia noted that having major depressive disorder doesn't just mean you are depressed, which is a description of a mood state. It's "depression plus other symptoms that become a clinical syndrome," he said.
Those symptoms may include insomnia, a loss of interest in things you used to love, or simply not taking pleasure in daily life. They are constant, lasting for longer than just one or two days, and can creep up on you, Garcia said.
Can a magnet help my mental health? How transcranial magnetic stimulation works in Austin.
Half of the people in the study will receive the BHV-7000 medication and half will receive a placebo. No one will know which group they have been assigned to.
Enrollees will continue taking the medication or the placebo for six weeks. After that part of the study concludes, they may opt to continue with the study and would be guaranteed to receive the medication for 52 weeks. Garcia said he feels better knowing that he can offer the medication to all participants after the initial study period ends.
While in the study, participants will receive free psychiatric care.
Such clinical trials "bring us closer to the understanding of how depression might come about," Garcia said. "It might be caused by a number of different mechanisms or issues."
Dell Medical School clinic at UT Austin joins global bipolar study for treatments
To find out more about the study and if they qualify, people can visit mddclinicalstudy.com or austinclinicaltrialpartners.com.
This article originally appeared on Austin American-Statesman: Austin doctor studying major depressive disorder medication
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18-07-2025
- Yahoo
Two Columbus Zoo elephants are expecting in the coming months
COLUMBUS, Ohio (WCMH) – It's an exciting time at the Columbus Zoo and Aquarium where not one, but two elephants are currently expecting. Experienced mama Phoebe and first-time mom Sunny are due in the coming months, which has the animal care team on baby watch. 'We've never had this opportunity to even have the ability to have two baby elephants at the same time. We are all-in with sustainability and conservation of Asian elephants and I cannot wait,' said Adam Felts, Senior Curator for the Columbus Zoo and Aquarium. With any pregnancy, it's a delicate balance of excitement, anticipation and specialized care, which these elephants are receiving around the clock. 'Fortunately, they are months apart, or at least four months apart,' said Dr. Randy Junge, Columbus Zoo's Vice President of Animal Health. 'If the babies have complications or the moms have complications, they can be really intensive cases. If you had two at the same time with complications, it could be really very difficult, but we're not anticipating any problems again both females are healthy.' Nationwide Arena announces $400 million renovation project Keeping them healthy and limber is a top priority for the elephant care team members like Laura Garcia, who, on this day, was leading Pheobe in her morning stretches. 'We do call it elephant yoga, and we want to keep our elephants in shape, especially our pregnant and elephants,' said Garcia. The team also does regular blood draws and ultrasounds to monitor mom and baby's health. 'At this stage, the baby isn't changing much, we just want to monitor and make sure there aren't any changes,' said Dr. Junge. As the moms-to-be enter their birth windows this summer, the excitement is mounting for everyone. 'It's very exciting that people get excited about this with us because it is such a special experience,' said Garcia. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Business Wire
30-06-2025
- Business Wire
GeNeuro Announces Approval of All Resolutions Proposed at Extraordinary General Meeting
GENEVA, Switzerland--(BUSINESS WIRE)--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that its shareholders have approved all resolutions proposed at its Extraordinary General Meeting (EGM) of 30 June 2025. 69.1% of the Company's share capital was present or represented at the EGM and resolutions were all unanimously approved. Detailed results will be available on the Company's website at: As mentioned in the invitation to the EGM, in order to ensure continuity of governance, this Extraordinary General Meeting had been called to vote on the re-election of the members of the Board of Directors, the Chairman of the Board of Directors and the Remuneration Committee, as well as the independent representative, until the next Ordinary General Meeting can be held. Following his re-election to the Board, Mr Jesús Martin-Garcia has been named Executive Chairman of the Company. As previously announced, following the disappointing results of its last Phase 2 clinical trial in Long COVID, the Company has launched a major restructuring, making redundant all employees at the parent company level, seeking and obtaining a debt-restructuring moratorium and launching a major effort to monetize its assets. Despite the end of their employment contract at the end of December 2024, both Jesús Martin-Garcia and Mr Miguel Payró have agreed to continue on a part-time basis to support the Company's efforts as Executive Chairman and Chief Financial Officer respectively. As for the 2024 financial statements, in view of the uncertainty surrounding the outcome of the asset monetization process, the Company had announced that it suspended publication of its financial statements. About GeNeuro GeNeuro's mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. For more information, visit: Disclaimer: This press release contains certain forward - looking statements and estimates concerning GeNeuro's financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words, such as 'anticipate,' 'believe,' 'can,' 'could,' 'estimate,' 'expect,' 'intend,' 'is designed to,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'objective,' 'should,' or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management's current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company's control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.
Boston Globe
29-06-2025
- Boston Globe
Max Fink, champion of electroconvulsive therapy, dies at 102
'Many severely depressed patients are maintained for weeks, for months and even years on antidepressant drugs,' he told a conference on depression in Philadelphia in 1988. 'Are we not unfair when we do this to our patients when ECT remains an active and excellent treatment?' He first witnessed the use of ECT in 1952, on his first day as a neurology and psychiatry resident at Hillside Hospital (now Zucker Hillside Hospital, a part of Northwell) in the New York City borough of Queens. One by one, he watched as five patients — under restraints, with rubber bite-blocks in their mouths and electrodes applied to their temples — received enough electrical current to induce a grand mal seizure. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up 'Observing a full grand mal seizure in each patient jarred me,' he wrote in 2017 in an unpublished memoir for Stony Brook University in New York, where he worked for many years. But over the next few months, he said, 'I had learned that ECT effectively reduced suicide thoughts, relieved negativism, aggression, depressed and manic moods. Of the hospital populations, the patients treated with electroshock improved the most.' Advertisement Although Dr. Fink was convinced of ECT's positive effects, others in the psychiatric profession weren't. Advertisement 'Max was trained in an era when the main theme of psychiatry was orthodox Freudian psychoanalysis,' said Dr. Charles Nemeroff, chair of the department of psychiatry and behavioral sciences at Dell Medical School at the University of Texas at Austin, who collaborated with Dr. Fink on a paper about ECT. 'But he was part of a small group of academic psychiatrists who recognized that severe depression and schizophrenia were brain diseases.' Dr. Fink, author of many scientific articles about ECT and founding editor of the quarterly Convulsive Therapy (now The Journal of ECT), faced opposition from other doctors, Scientologists and protesters at conferences. 'We had a problem getting this accepted by the public, and I was protested at meetings across the United States and Europe,' he said in 2019, when he received an award for lifetime achievement from the Institute of Living, a psychiatric center in Hartford, Connecticut. Some opponents of ECT said it was ineffective or left people with memory loss and trauma. Others described it as a brutal practice, an enduring view reinforced by the 1975 film 'One Flew Over the Cuckoo's Nest,' in which a patient at a psychiatric hospital, played by Jack Nicholson, undergoes ECT without anesthesia as a punishment for his rebelliousness. In his book 'Electroshock: Healing Mental Illness' (1999), Dr. Fink wrote that 'the picture of a pleading patient being dragged to a treatment room, where he is forcibly administered electric currents, as his jaw clenches, his back arches, his body shakes, all the while he is held down by burly attendants, may be dramatic but it is wholly false. Patients aren't coerced into treatment.' Advertisement Critics of Dr. Fink's passionate support of ECT said he downplayed the risks, including memory loss and cognitive impairment. 'One of Fink's books describes going to get ECT as no more significant than going to the dentist, which I thought was pretty glib,' said Jonathan Sadowsky, author of 'Electroconvulsive Therapy in America: The Anatomy of a Medical Controversy' (2017). 'And there are a lot of scientific studies about memory loss from ECT.' Dr. Fink insisted that antidepressants and antipsychotics could cause more damage, including memory loss, than ECT did. Nemeroff — who described Dr. Fink as 'an irascible, dominant figure' as well as 'the world's leader in electroconvulsive therapy' — said Dr. Fink's focus was firmly on the effectiveness of the treatment. 'He was a zealot, no question about it,' Nemeroff said. 'He thought ECT was a panacea.' ECT's effectiveness in treating serious mental illness has been recognized by, among others, the American Psychiatric Association, the American Medical Association and the National Institute of Mental Health. But although it is useful for treating serious mental illness, it does not prevent recurrence. Consequently, most people treated with ECT need to continue the procedure or use another type of maintenance treatment. Maximilian Fink was born Jan. 16, 1923, in Vienna. His father, Julius, was a doctor in general practice who was trained in radiology. His mother, Bronislava (Lowenthal) Fink, known as Bronia, left medical school at the University of Vienna after three years; later, in the mid-1950s, she became a social worker. Max and his mother immigrated to the United States in 1924, joining his father there. (His brother, Sidney, who was born in 1927, also became a doctor, specializing in gastroenterology.) Advertisement As a boy, Max developed X-ray film in his father's office. He started college at 16, at New York University's University Heights campus in the Bronx, and graduated in three years, with a bachelor's degree in biology, in 1942. After earning his medical degree at the NYU College of Medicine (now the Grossman School of Medicine) three years later and interning at Morrisania Hospital in the Bronx, he served in the Army from 1946-47, attending the School of Military Neuropsychiatry. After his discharge from the Army, he worked as a surgeon on three passenger ships. From 1948-53, Dr. Fink served as a resident at Montefiore, Bellevue, Hillside and Mount Sinai hospitals. From 1954-62, he ran the division of experimental psychiatry at Hillside. He later served as director of the Missouri Institute of Psychiatry and as a professor of psychiatry at New York Medical College. From 1972-97, he was a professor of psychiatry and neurology at Stony Brook University, where he later became a professor emeritus. Dr. Fink's research had unusual breadth. He showed early in his research career that penicillin, still an experimental drug, was better than sulfa for patients with pleural cavity infections. He studied the pharmacology of LSD, marijuana and opioids; used electroencephalograms, or EEG tests, to measure the changes caused by electroshock, insulin coma and psychoactive drugs; and wrote about the effects of changing the placements of electrodes in ECT. He was also among the scholars who successfully argued for the recognition of catatonia — a syndrome characterized by irregular movements and immobility — by the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, or DSM, as separate from schizophrenia. Advertisement Dr. Fink's other books include 'Convulsive Therapy: Theory and Practice' (1979), 'Electroshock: Restoring the Mind' (1999), 'Ethics in Electroconvulsive Therapy' (2004, with Jan-Otto Ottosson) and 'The Madness of Fear: A History of Catatonia' (2018, with Edward Shorter). He wrote or collaborated on about 800 scientific papers, including one on catatonia that was accepted for publication by Journal of the Academy of Consultation-Liaison Psychiatry shortly before his death. In addition to his son, Dr. Fink is survived by two daughters, Rachel and Linda, and four grandchildren. His wife, Martha (Gross) Fink, died in 2016. In a 2018 interview for Stony Brook, Dr. Fink reflected on his career and its influence. 'I think I was very lucky,' he said. 'However I worked it out, I was always able to find projects and kept busy.' He later added: 'We've saved lives knowingly. It's been a very interesting life.' This article originally appeared in
